SAB4700545
Monoclonal Anti-TUBB3-FITC antibody produced in mouse
clone TU-20, purified immunoglobulin, buffered aqueous solution
Synonym(s):
Anti-βIII-tubulin
Sign Into View Organizational & Contract Pricing
Select a Size
About This Item
UNSPSC Code:
12352203
NACRES:
NA.41
biological source
mouse
conjugate
FITC conjugate
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
TU-20, monoclonal
form
buffered aqueous solution
species reactivity
wide range
concentration
1 mg/mL
technique(s)
flow cytometry: suitable
isotype
IgG1
NCBI accession no.
shipped in
wet ice
storage temp.
2-8°C
target post-translational modification
unmodified
Gene Information
human ... TUBB3(10381)
General description
The antibody TU-20 recognizes C-terminal peptide sequence ESESQGPK (aa 441-448) of neuron-specific human betaIII-tubulin.
Tubulin β 3 class III (TUBB3) also known as β-tubulin III, is encoded by the gene mapped to human chromosome 16q24.3. TUBB3 protein expression is restricted to neurons.
Immunogen
Peptide (C) 441-448 coupled to maleimide-activated keyhole limpet hemocyanin via cysteine added to the N-terminus of the neuron-specific peptide
Application
Monoclonal Anti-TUBB3-FITC antibody produced in mouse has been used in immunoassays.
The reagent is designed for Flow Cytometry analysis. Suggested working dilution is 1:40. Indicated dilution is recommended starting point for use of this product. Working concentrations should be determined by the investigator.
Biochem/physiol Actions
Tubulin β 3 class III (TUBB3) plays a vital role in nervous system development and axon guidance. Mutation of the gene encoding protein leads to the ocular motility disorder, congenital fibrosis of the extraocular muscle type 3 (CFEOM3), and various neurological syndromes. Altered expression of the protein affects microtubule dynamics and microtubule-kinesin interactions. Increased expression of TUBB3 is observed in tumor tissues. Decreased expression of TUBB3 can be considered as an important marker for poor prognosis of cutaneous malignant melanoma. TUBB3 is implicated in the suppression of invasive growth of tumor tissue. Thus, it is considered to be a potential target for development of antitumor drugs.
Features and Benefits
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
Physical form
Solution in phosphate buffered saline, pH 7.4, with 15 mM sodium azide.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
12 - Non Combustible Liquids
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Monozygotic twins with a de novo 0.32?Mb 16q24.3 deletion, including TUBB3 presenting with developmental delay and mild facial dysmorphism but without overt brain malformation.
Gr?nborg S
American Journal of Medical Genetics. Part A, 167A, 2731-2736 (2015)
Human TUBB3 mutations perturb microtubule dynamics, kinesin interactions, and axon guidance.
Tischfield MA
Cell, 140, 74-87 (2010)
BETA-III TUBULIN AS A POTENTIAL TARGET FOR BLOCKING INVASIVE GROWTH OF MALIGNANT EPITHELIAL TUMORS
Portyanko AS
Eksperimental'naia i Klinicheskaia Farmakologiia, 78, 25-28 (2015)
Tumoral and tissue-specific expression of the major human beta-tubulin isotypes.
Leandro-Garcia LJ
Cytoskeleton (Hoboken, N.J.), 67, 214-223 (2010)
Decreased expression of class III β-tubulin is associated with unfavourable prognosis in patients with malignant melanoma.
Shimizu A
Melanoma Research, 26, 29-34 (2016)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service